I'm LongbridgeAI, I can summarize articles.The Week
iShares Global Healthcare (IXJ) gained 1.58% this week to close at $114.74 on Friday, trailing the S&P 500’s 2.51% advance by about 0.93 percentage points. Trading was rangebound, with weekly amplitude near 1.95%. The fund opened Monday at $114.01, touched a weekly high of $115.56 on Thursday, and settled back to $114.74 on Friday. The 20-day moving average sits at $111.81 and the 60-day at $106.34, leaving the price above both.
Sector News
Healthcare news was dense this week, with obesity drugs and regulatory approvals at the centre. Eli Lilly’s oral GLP-1RA orforglipron won China’s NMPA approval, making it the first oral weight-loss pill cleared there. Lilly also reported positive 52-week results from the TOGETHER-PsA trial and began building a $3.5 billion obesity drug plant in Pennsylvania. Merck’s efinopegdutide met its primary endpoint in a Phase 2b MASH trial, with resolution rates up to 63%. Johnson & Johnson’s Caplyta reduced bipolar mania symptoms in a second Phase 3 trial, while Amgen’s dazodalibep lowered Sjogren’s disease activity in Phase 3. AstraZeneca received FDA approval for its IMFINZI bladder cancer regimen and a positive EU panel opinion for Baxfendy. J&J also faced talc-related litigation, with a California jury awarding $34.21 million and a separate Massachusetts order of $3.3 million.
The Week Ahead
The macro calendar next week centres on retail and industrial data. On Tuesday 17 November, US retail sales are due with prior 0.8% and forecast 0.2%; retail sales ex-autos prior 0.9% and forecast 0.4%; import prices prior 8.1%; industrial production prior 0.7% and forecast 0.1%; and the NAHB housing market index prior 29 and forecast 29. On Monday 16 November, the New York Fed manufacturing index is due with prior 25.5 and forecast 18. Whether the sector’s pipeline and approval momentum carries over, and how macro consumption data shapes risk appetite, will be the early focus.
In Short
IXJ rose this week but lagged the broader market, with healthcare showing internal divergence: obesity-drug and approval catalysts supported gains, while J&J litigation and some single-stock weakness weighed. Valuation is moderate, with P/E around 14.64x and P/B around 1.39x. The latest session’s fund flows were mixed, with medium-sized orders net sellers and small orders net buyers. Going forward, watch how retail data affects overall risk appetite and whether the obesity-drug approval translates into sustained sector upside.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.